Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha-synuclein PET tracer
- Development stage
- Preclinical
- Lead developer
- APRINOIA Therapeutics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The alpha-synuclein PET tracer is a preclinical-stage, small molecule diagnostic imaging agent being developed by APRINOIA Therapeutics. It is designed to selectively bind to pathological alpha-synuclein (α-Syn) aggregates in the brain, which are the hallmark of synucleinopathies. By enabling the visualization and quantification of these aggregates via positron emission tomography (PET) imaging, the tracer aims to provide a precise diagnostic tool for conditions such as Parkinson's disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). The program has received support from The Michael J. Fox Foundation for Parkinson's Research and is part of APRINOIA's proprietary platform targeting aggregated protein structures to facilitate both early diagnosis and the monitoring of disease-modifying therapies.
- Other names
- αSyn PET Traceralpha-synuclein PET imaging agentalpha-synuclein PET probe
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))Amyloid fibrilsTau aggregates (Microtubule-associated protein tau (pathological form))
Beyond the preview
Go deeper on alpha-synuclein PET tracer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha-synuclein PET tracer.